SAB Biotherapeutics (NASDAQ:SABS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its earnings results on Wednesday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%.

SAB Biotherapeutics Stock Up 7.3 %

SAB Biotherapeutics stock traded up $0.24 during mid-day trading on Friday, reaching $3.51. 86,453 shares of the company were exchanged, compared to its average volume of 29,686. SAB Biotherapeutics has a twelve month low of $2.16 and a twelve month high of $9.72. The firm’s 50-day simple moving average is $2.90 and its two-hundred day simple moving average is $3.01. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

SABS has been the subject of a number of research analyst reports. Craig Hallum initiated coverage on SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research report on Thursday. Oppenheimer reissued an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research report on Thursday, September 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.